Real-life intraclass switch among IL-17 inhibitors in psoriasis: results from a single-centre, 24-week, retrospective study.

Sotiriou, E; Bakirtzi, K; Papadimitriou, I; Tsentemeidou, A; Kougkas, N; Panagopoulou, A; Ioannides, D; Vakirlis, E

Sotiriou, E; Bakirtzi, K; Papadimitriou, I; Tsentemeidou, A; Kougkas, N; Panagopoulou, A; Ioannides, D; Vakirlis, E.

Affiliation

Sotiriou E; First Department of Dermatology and Venereology, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Bakirtzi K; First Department of Dermatology and Venereology, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Papadimitriou I; First Department of Dermatology and Venereology, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Tsentemeidou A; First Department of Dermatology and Venereology, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Kougkas N; Fourth Department of Internal Medicine, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Panagopoulou A; First Department of Dermatology and Venereology, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Ioannides D; First Department of Dermatology and Venereology, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Vakirlis E; First Department of Dermatology and Venereology, Aristotle University of Thessaloniki, Thessaloniki, Greece.

J Eur Acad Dermatol Venereol ; 36(11): e952-e953, 2022 11.

Article in En | MEDLINE | ID: mdl-35770467

Subject(s)

Interleukin-17; Psoriasis; Antibodies, Monoclonal, Humanized; Humans; Psoriasis/drug therapy; Retrospective Studies; Severity of Illness Index; Treatment Outcome

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Psoriasis / Interleukin-17 Type of study: Observational_studies / Risk_factors_studies Limits: Humans Language: En Journal: J Eur Acad Dermatol Venereol Year: 2022 Document type: Article

Fulltext

XML

PubMed Links

Search on Google